Clinical Report: Oculomics Device Wins UK Funding
Overview
Occuity has received a £1.5 million grant to develop a handheld device for diabetes screening through eye scans. The SD1 device aims to assess diabetes risk by measuring advanced glycation end-products in the eye's crystalline lens.
Background
Diabetes poses a significant burden on healthcare systems, being a leading cause of severe complications such as kidney failure and blindness. Early identification of individuals at risk for diabetes is crucial for effective intervention and prevention. Current screening methods often require blood samples, which can be a barrier to access for many individuals.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
- Occuity's SD1 device is designed for non-invasive diabetes risk assessment through eye scans.
- The device measures advanced glycation end-products (AGEs) linked to long-term glucose exposure.
- Funding was awarded through Innovate UK's Biomedical Catalyst 2025 program, with a success rate of 2.3% from 347 applications.
- Community optometry can facilitate earlier identification of individuals at risk for diabetes.
- Existing prevention programs can delay or prevent progression to type 2 diabetes, but early identification remains a challenge.
Clinical Implications
The SD1 device is designed for non-invasive diabetes risk assessment through eye scans, potentially facilitating earlier identification of individuals at risk for diabetes.
Conclusion
The development of the SD1 device is focused on advancing diabetes screening technology.
Related Resources & Content
- Occuity, Innovate UK, 2023 -- Oculomics Device Wins UK Funding
- Optometric Management — Maintain a consistent style on Instagram and TikTok
- Optometric Management — Create an Itemized Fee Schedule
- Optometric Management — Optos Celebrates 30000 Worldwide Device Installations
- Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
- Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
- Role of retinal biomarkers in diabetes detection and risk prediction: A systematic scoping review - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
